Silver Spring, Maryland, USA, November 17, 2026
The U.S. Food and Drug Administration (FDA) has launched the Global Reliance Disclosure Program (GRDP), a new regulatory initiative designed to expand patient access to medicines worldwide by sharing detailed drug and biologics approval assessments with international health authorities. Announced on November 17, 2026, the programme aims to help regulatory agencies outside the United States make use of the FDA’s scientific and regulatory evaluations when reviewing applications for medicines in their respective countries. Through the initiative, pharmaceutical and biotechnology companies can request minimally redacted FDA approval packages and share these documents with foreign regulatory authorities to support marketing applications. The programme is intended to reduce duplicated regulatory work, improve international regulatory collaboration and potentially shorten the time patients wait for access to innovative treatments. Importantly, participating countries will retain their independent authority to make their own regulatory decisions.
FDA Introduces a New Global Regulatory Reliance Framework
The Global Reliance Disclosure Program addresses a longstanding challenge in international medicine development: differences in the time required for regulatory approval across countries. Although a medicine may receive FDA approval following an extensive scientific review, patients in other regions can experience additional delays while their national regulatory authorities conduct separate evaluations. These delays can be particularly challenging in countries with limited regulatory resources and technical capacity. Under the GRDP, the FDA will make approval packages containing its detailed scientific and regulatory assessments available to eligible applicants. Companies can then provide these documents to health authorities outside the United States to support their local marketing authorization applications. The information is intended to help regulators understand the evidence reviewed by the FDA, including its scientific conclusions and regulatory rationale. The programme does not transfer regulatory decision-making authority to the FDA or automatically approve medicines in other countries. Instead, it provides international regulators with access to established scientific assessments that they may consider when making their own decisions. The initiative is also intended to encourage greater consistency in regulatory standards and support global public health security.
Lenacapavir Marks the Programme’s First Application
The FDA launched the GRDP on October 30, 2026, with a tentative approval under the President’s Emergency Plan for AIDS Relief (PEPFAR) involving lenacapavir, a medicine indicated for HIV prevention and treatment. This initial application reflects the programme’s potential relevance to global health priorities, particularly improving access to medicines for populations affected by HIV/AIDS. At its launch, the programme was initially limited to PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug applications (ANDAs) for generic products. The FDA has outlined plans to broaden eligibility in January 2027 to include all novel drugs and biological products. This expansion is expected to cover New Molecular Entity (NME) New Drug Applications and 351(a) Biologics License Applications (BLAs). By extending the initiative to a wider range of innovative medicines and biologics, the agency aims to make its scientific assessments more accessible to regulators worldwide. The FDA also intends to introduce a separate pathway in early 2027 that will allow companies to request minimally redacted approval packages for medicines and biological products that have already received U.S. approval or licensure.
Application Requirements and Future Programme Expansion
Companies seeking to participate in the GRDP must follow specific submission requirements. Applicants must request participation within 10 calendar days of receiving FDA approval and confirm that the approval package will be submitted to a foreign regulatory authority in support of a marketing application. Eligible applicants will receive programme-related information in their FDA approval letters, and the agency intends to provide the requested documents on an expedited basis. Requests for approval packages intended for purposes other than supporting foreign marketing applications will not be processed through the GRDP and must instead follow the standard Freedom of Information Act (FOIA) request process. These requirements are intended to ensure that the programme directly supports international regulatory submissions rather than serving as a general document-disclosure mechanism. The FDA has described the initiative as an important step towards improving global regulatory collaboration. By making its scientific assessments available to international regulators, the agency expects to help reduce unnecessary duplication and support more efficient evaluation of medicines across different markets. The programme may be particularly valuable for countries where limited resources can make independent regulatory reviews more time-consuming. However, each participating country’s health authority will continue to assess applications according to its own legal and regulatory requirements.
The Global Reliance Disclosure Program represents a significant development in international pharmaceutical regulation. Its planned expansion in 2027 could create new opportunities for companies developing innovative medicines and biologics to support regulatory submissions across multiple countries. The programme’s long-term impact will depend on international regulatory participation and how effectively health authorities incorporate shared FDA assessments into their national review processes.
Source: FDA press release



